6,340
Views
91
CrossRef citations to date
0
Altmetric
Original Research

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

, , , , , , , , ORCID Icon, , , , , , , ORCID Icon, & show all
Article: e1380764 | Received 17 May 2017, Accepted 13 Sep 2017, Published online: 16 Oct 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Esther Schoutrop, Stefanie Renken, Isabella Micallef Nilsson, Paula Hahn, Thomas Poiret, Rolf Kiessling, Stina L Wickström, Jonas Mattsson & Isabelle Magalhaes. (2022) Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. OncoImmunology 11:1.
Read now
Othman Mohammad Saleh, Khaled Anwer Albakri, Yasmeen Jamal Alabdallat, Majd Hamdi Dajani & Walaa Bayoumie El Gazzar. (2022) The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers 27:1, pages 22-34.
Read now
Linlin Zhao, Tong Lian, Jianmin Li, Shiyao Wei, Hongjie Li, Changying Li & Haitao Wang. (2021) NCR3LG1 (B7-H6) is a potential prognostic factor for bladder cancer patients. Biomarkers 26:3, pages 260-267.
Read now
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, Sabine Tejpar, Peter Vandenberghe, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2020) Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology 9:1.
Read now
Haiyuan Yu, Jun Pan, Zhicheng Guo, Chunhua Yang & Lijun Mao. (2019) CART cell therapy for prostate cancer: status and promise. OncoTargets and Therapy 12, pages 391-395.
Read now

Articles from other publishers (86)

Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K. Park, Jianming Lu, Sang-In Kim, Hannah Valencia, Yuman Fong & Yanghee Woo. (2023) Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases. Molecular Therapy - Oncolytics 31, pages 100734.
Crossref
Faezeh Ramezani, Ahmad Reza Panahi Meymandi, Behnia Akbari, Omid Reza Tamtaji, Hamed Mirzaei, Christine E. Brown & Hamid Reza Mirzaei. (2023) Outsmarting trogocytosis to boost CAR NK/T cell therapy. Molecular Cancer 22:1.
Crossref
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica M. Pezold, John Meekin, Chien-ying Chang, Rosa A. Carrasco, Shannon Breen, Crystal Sao-Fong Cheung, Ariel Endlich-Frazier, Benjamin Clark, Nina J. Chu, Alessio Vantellini, Philip L. Martin, Clare E. Hoover, Kenesha Riley, Steve M. Sweet, David Chain, Yeoun Jin Kim, Eric Tu, Nathalie Harder, Sandrina Phipps, Melissa Damschroder, Ryan N. Gilbreth, Mark Cobbold, Gordon Moody & Emily E. Bosco. (2023) Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. Journal of Clinical Investigation 133:22.
Crossref
Dhivya Sridaran, Elliot Bradshaw, Carl DeSelm, Russell Pachynski, Kiran Mahajan & Nupam P. Mahajan. (2023) Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach. Cell Reports Medicine 4:10, pages 101199.
Crossref
Eric Hee Jun Lee, John P. Murad, Lea Christian, Jackson Gibson, Yukiko Yamaguchi, Cody Cullen, Diana Gumber, Anthony K. Park, Cari Young, Isabel Monroy, Jason Yang, Lawrence A. Stern, Lauren N. Adkins, Gaurav Dhapola, Brenna Gittins, Wen-Chung Chang, Catalina Martinez, Yanghee Woo, Mihaela Cristea, Lorna Rodriguez-Rodriguez, Jun Ishihara, John K. Lee, Stephen J. Forman, Leo D. Wang & Saul J. Priceman. (2023) Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nature Communications 14:1.
Crossref
Zhibo Zheng, Siyuan Li, Mohan Liu, Chuyan Chen, Lu Zhang & Daobin Zhou. (2023) Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. Cancers 15:13, pages 3476.
Crossref
Angela Q. Zhang, Alexander Hostetler, Laura E. Chen, Vainavi Mukkamala, Wuhbet Abraham, Lucia T. Padilla, Alexandra N. Wolff, Laura Maiorino, Coralie M. Backlund, Aereas Aung, Mariane Melo, Na Li, Shengwei Wu & Darrell J. Irvine. (2023) Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nature Biomedical Engineering.
Crossref
Ji-Young Choi & Tae-Jin Kim. (2023) The Current Status and Future Perspectives of Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Endometrial Cancer. Current Issues in Molecular Biology 45:4, pages 3359-3374.
Crossref
Mohamad Hamieh, Jorge Mansilla-Soto, Isabelle Rivière & Michel Sadelain. (2023) Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. Cancer Discovery 13:4, pages 829-843.
Crossref
Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Audrey Jung, Jianming Lu, Sang-In Kim, Saul Priceman, Yuman Fong & Yanghee Woo. (2023) Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. Journal for ImmunoTherapy of Cancer 11:4, pages e006280.
Crossref
Laeeq ur Rehman, Muhammad Hassan Nisar, Wajeeha Fatima, Azza Sarfraz, Nishwa Azeem, Zouina Sarfraz, Karla Robles-Velasco & Ivan Cherrez-Ojeda. (2023) Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives. Journal of Clinical Medicine 12:4, pages 1446.
Crossref
Yun Tian, Zhenzhu Liu, Jianbo Wang, Linan Li, Fuli Wang, Zheng Zhu & Xuejian Wang. (2023) Nanomedicine for Combination Urologic Cancer Immunotherapy. Pharmaceutics 15:2, pages 546.
Crossref
Rong Luan & Biping Deng. (2023) T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma. Hematology and Oncology Discovery 2:1.
Crossref
Renate Starr, Brenda Aguilar, Diana Gumber, Madeleine Maker, Stephanie Huard, Dongrui Wang, Wen-Chung Chang, Alfonso Brito, Vivian Chiu, Julie R. Ostberg, Benham Badie, Stephen J. Forman, Darya Alizadeh, Leo D. Wang & Christine E. Brown. (2023) Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells. Cancer Research Communications 3:1, pages 66-79.
Crossref
Dongrui Wang, Xin Yang, Agata Xella, Lawrence A. Stern & Christine E. Brown. 2023. The Immunological Synapse Part A. The Immunological Synapse Part A 173 189 .
. 2023. An Insider's Perspective of Prostate Cancer. An Insider's Perspective of Prostate Cancer 113 141 .
Elena I. Fomchenko, James C. Bayley, Christopher Alvarez-Breckenridge, Laurence D. Rhines & Claudio E. Tatsui. (2022) Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. Neurospine 19:4, pages 978-993.
Crossref
Xinhui Li, Jian Zhou, Weiwen Zhang, Wenhua You, Jun Wang, Linlin Zhou, Lei Liu, Wei-Wei Chen & Hanjie Li. (2022) Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates. Cancers 14:22, pages 5674.
Crossref
Marzieh Mazinani & Fatemeh Rahbarizadeh. (2022) CAR-T cell potency: from structural elements to vector backbone components. Biomarker Research 10:1.
Crossref
Zhengchao Zhang, Dong Li, Heng Yun, Wei Liu, Keqiang Chai, Jie Tong, Tongwei Zeng, Zhenghua Gao & Yongqiang Xie. (2022) CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. Frontiers in Oncology 12.
Crossref
Jiangang Sun, Xiaojing Li, Peng Chen & Yongshun Gao. (2022) From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. Journal of Inflammation Research Volume 15, pages 4061-4085.
Crossref
Alaa Alnefaie, Sarah Albogami, Yousif Asiri, Tanveer Ahmad, Saqer S. Alotaibi, Mohammad M. Al-Sanea & Hisham Althobaiti. (2022) Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S Lopez, Rachel H Ng, Neena Leggett, Vanessa D Jonsson, Jelani C Zarif, Peter P Lee, Xiuli Wang, Catalina Martinez, Tanya B Dorff, Stephen J Forman & Saul J Priceman. (2022) PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. Journal for ImmunoTherapy of Cancer 10:6, pages e004400.
Crossref
Kun-Yu Teng, Anthony G. Mansour, Zheng Zhu, Zhiyao Li, Lei Tian, Shoubao Ma, Bo Xu, Ting Lu, Hanyu Chen, David Hou, Jianying Zhang, Saul J. Priceman, Michael A. Caligiuri & Jianhua Yu. (2022) Off-the-Shelf Prostate Stem Cell Antigen–Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. Gastroenterology 162:4, pages 1319-1333.
Crossref
Xiaohui Si, Lu Xiao, Christine E. Brown & Dongrui Wang. (2022) Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models. International Journal of Molecular Sciences 23:6, pages 3154.
Crossref
Zhifang Zhang, Annie Yang, Shyambabu Chaurasiya, Anthony K. Park, Sang-In Kim, Jianming Lu, Tove Olafsen, Susanne G. Warner, Yuman Fong & Yanghee Woo. (2022) PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1. Molecular Therapy - Oncolytics 24, pages 331-339.
Crossref
Yao Jiang, Weihong Wen, Fa Yang, Donghui Han, Wuhe Zhang & Weijun Qin. (2022) Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy. Cancers 14:4, pages 967.
Crossref
Tanya B. Dorff, Vivek Narayan, Stephen J. Forman, Peter D. Zang, Joseph A. Fraietta, Carl H. June, Naomi B. Haas & Saul J. Priceman. (2022) Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer. Clinical Cancer Research 28:4, pages 576-584.
Crossref
Saeed Rafii, Emad Tashkandi, Nedal Bukhari & Humaid O. Al-Shamsi. (2022) Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges. Cancers 14:4, pages 947.
Crossref
Jorge Mansilla-Soto, Justin Eyquem, Sascha Haubner, Mohamad Hamieh, Judith Feucht, Noémie Paillon, Andrés Ernesto Zucchetti, Zhuoning Li, Maria Sjöstrand, Pieter L. Lindenbergh, Michelle Saetersmoen, Anton Dobrin, Mathieu Maurin, Archana Iyer, Andreina Garcia Angus, Matthew M. Miele, Zeguo Zhao, Theodoros Giavridis, Sjoukje J. C. van der Stegen, Fella Tamzalit, Isabelle Rivière, Morgan Huse, Ronald C. Hendrickson, Claire Hivroz & Michel Sadelain. (2022) HLA-independent T cell receptors for targeting tumors with low antigen density. Nature Medicine 28:2, pages 345-352.
Crossref
Mahasha P.J. Perera, Patrick B. Thomas, Gail P. Risbridger, Renea Taylor, Arun Azad, Michael S. Hofman, Elizabeth D. Williams & Ian Vela. (2022) Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers 14:3, pages 503.
Crossref
Kathryn M. Cappell & James N. Kochenderfer. (2021) A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nature Reviews Clinical Oncology 18:11, pages 715-727.
Crossref
Philipp Wolf, Jamal Alzubi, Christian Gratzke & Toni Cathomen. (2021) The potential of CAR T cell therapy for prostate cancer. Nature Reviews Urology 18:9, pages 556-571.
Crossref
Lele Miao, Zhengchao Zhang, Zhijian Ren & Yumin Li. (2021) Application of Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Xuexiao Jin, Qin Xu, Chengfei Pu, Kaixiang Zhu, Cheng Lu, Yu Jiang, Lei Xiao, Yongmei Han & Linrong Lu. (2020) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cellular & Molecular Immunology 18:8, pages 1896-1903.
Crossref
Archana Thakur, John Scholler, Ewa Kubicka, Edwin T. Bliemeister, Dana L. Schalk, Carl H. June & Lawrence G. Lum. (2021) Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells. Frontiers in Immunology 12.
Crossref
John P. Murad, Dileshni Tilakawardane, Anthony K. Park, Lupita S. Lopez, Cari A. Young, Jackson Gibson, Yukiko Yamaguchi, Hee Jun Lee, Kelly T. Kennewick, Brenna J. Gittins, Wen-Chung Chang, Chau P. Tran, Catalina Martinez, Anna M. Wu, Robert E. Reiter, Tanya B. Dorff, Stephen J. Forman & Saul J. Priceman. (2021) Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Molecular Therapy 29:7, pages 2335-2349.
Crossref
Esther Schoutrop, Ibrahim El-Serafi, Thomas Poiret, Ying Zhao, Okan Gultekin, Rui He, Lidia Moyano-Galceran, Joseph W. Carlson, Kaisa Lehti, Moustapha Hassan, Isabelle Magalhaes & Jonas Mattsson. (2021) Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Cancer Research 81:11, pages 3022-3035.
Crossref
Jing-e Zhou, Jing Yu, Yeying Wang, Hao Wang, Jing Wang, Yiting Wang, Lei Yu & Zhiqiang Yan. (2021) ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomedicine & Pharmacotherapy 137, pages 111339.
Crossref
Devivasha Bordoloi, Peng Xiao, Hyeree Choi, Michelle Ho, Alfredo Perales-Puchalt, Makan Khoshnejad, J. Joseph Kim, Laurent Humeau, Alagarsamy Srinivasan, David B. Weiner & Kar Muthumani. (2021) Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens. Genes & Cancer 12, pages 51-64.
Crossref
Lucia Morales & Jesús M. Paramio. (2021) Cell Therapies in Bladder Cancer Management. International Journal of Molecular Sciences 22:6, pages 2818.
Crossref
Chiara Donini, Ramona Rotolo, Alessia Proment, Massimo Aglietta, Dario Sangiolo & Valeria Leuci. (2021) Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. Cells 10:3, pages 543.
Crossref
Ana Textor, Laura Grunewald, Kathleen Anders, Anika Klaus, Silke Schwiebert, Annika Winkler, Maria Stecklum, Jana Rolff, Anton G. Henssen, Uta E. Höpken, Angelika Eggert, Johannes H. Schulte, Michael C. Jensen, Thomas Blankenstein & Annette Künkele. (2021) CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. Cancers 13:5, pages 1050.
Crossref
Justin R. Gregg & Timothy C. Thompson. (2021) Considering the potential for gene-based therapy in prostate cancer. Nature Reviews Urology 18:3, pages 170-184.
Crossref
Christina Amatya, Melissa A. Pegues, Norris Lam, Danielle Vanasse, Claudia Geldres, Stephanie Choi, Stephen M. Hewitt, Steven A. Feldman & James N. Kochenderfer. (2021) Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Molecular Therapy 29:2, pages 702-717.
Crossref
Young Dong Yu & Tae Jin Kim. (2021) Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences 22:2, pages 640.
Crossref
Chiara Pisano, Marcello Tucci, Rosario Francesco Di Stefano, Fabio Turco, Giorgio Vittorio Scagliotti, Massimo Di Maio & Consuelo Buttigliero. (2021) Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. Critical Reviews in Oncology/Hematology 157, pages 103185.
Crossref
Di Wu, Jiang Lv, Ruocong Zhao, Zhiping Wu, Diwei Zheng, Jingxuan Shi, Simiao Lin, Suna Wang, Qiting Wu, Youguo Long, Peng Li & Yao Yao. (2020) PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research 8:1.
Crossref
Hao Zhang, Pu Zhao & He Huang. (2020) Engineering better chimeric antigen receptor T cells. Experimental Hematology & Oncology 9:1.
Crossref
J. Feucht & M. Sadelain. (2020) Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors. Immuno-Oncology Technology 8, pages 2-11.
Crossref
Brooke Prinzing, Patrick Schreiner, Matthew Bell, Yiping Fan, Giedre Krenciute & Stephen Gottschalk. (2020) MyD88/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight 5:21.
Crossref
Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo & Stephen Gottschalk. (2020) CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. Molecular Therapy 28:11, pages 2320-2339.
Crossref
Giuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, Giorgia Gurioli, Lorena Rossi, Valentina Gallà, Maria Concetta Cursano, Nicole Brighi, Cristian Lolli, Cecilia Menna, Alberto Farolfi, Salvatore Luca Burgio, Amelia Altavilla, Giovanni Martinelli & Ugo De Giorgi. (2020) Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. Frontiers in Oncology 10.
Crossref
Anthony K. Park, Yuman Fong, Sang-In KimJason Yang, John P. MuradJianming LuBrook Jeang, Wen-Chung Chang, Nanhai G. ChenSandra H. Thomas, Stephen J. FormanSaul J. Priceman. (2020) Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Science Translational Medicine 12:559.
Crossref
Jayapriya Jayaraman, Michael P. Mellody, Andrew J. Hou, Ruchi P. Desai, Audrey W. Fung, An Huynh Thuy Pham, Yvonne Y. Chen & Weian Zhao. (2020) CAR-T design: Elements and their synergistic function. EBioMedicine 58, pages 102931.
Crossref
Zhendong Li, Zhixia Chi, Wei-Xia Ang, Can Chen, Johan CK Tay, Yu-Yang Ng, Xuehu Xu, Junjian Wang, Jianqing Zhu & Shu Wang. (2020) Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR. Immunotherapy 12:10, pages 733-748.
Crossref
Elena Maryamchik, Kathleen Mary Ellen Gallagher, Frederic I. Preffer, Stephan Kadauke & Marcela V. Maus. (2020) New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry. Cytometry Part B: Clinical Cytometry 98:4, pages 299-327.
Crossref
Nico M. Sievers, Jan Dörrie & Niels Schaft. (2020) CARs: Beyond T Cells and T Cell-Derived Signaling Domains. International Journal of Molecular Sciences 21:10, pages 3525.
Crossref
Danica Chiu, Richard Tavaré, Lauric Haber, Olulanu H. Aina, Kristin Vazzana, Priyanka Ram, Makenzie Danton, Jennifer Finney, Sumreen Jalal, Pamela Krueger, Jason T. Giurleo, Dangshe Ma, Eric Smith, Gavin Thurston, Jessica R. Kirshner & Alison Crawford. (2020) A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. Cancer Immunology Research 8:5, pages 596-608.
Crossref
Robbie G. Majzner, Skyler P. Rietberg, Elena Sotillo, Rui Dong, Vipul T. Vachharajani, Louai Labanieh, June H. Myklebust, Meena Kadapakkam, Evan W. Weber, Aidan M. Tousley, Rebecca M. Richards, Sabine Heitzeneder, Sang M. Nguyen, Volker Wiebking, Johanna Theruvath, Rachel C. Lynn, Peng Xu, Alexander R. Dunn, Ronald D. Vale & Crystal L. Mackall. (2020) Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discovery 10:5, pages 702-723.
Crossref
Yanghee Woo, Zhifang Zhang, Annie Yang, Shyambabu Chaurasiya, Anthony K. Park, Jianming Lu, Sang-In Kim, Susanne G. Warner, Daniel Von Hoff & Yuman Fong. (2020) Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. Journal of the American College of Surgeons 230:4, pages 709-717.
Crossref
Benjamin I. Philipson, Roddy S. O’Connor, Michael J. MayCarl H. June, Steven M. AlbeldaMichael C. Milone. (2020) 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Science Signaling 13:625.
Crossref
Dongrui Wang, Renate Starr, Wen-Chung Chang, Brenda AguilarDarya AlizadehSarah L. Wright, Xin Yang, Alfonso BritoAniee SarkissianJulie R. OstbergLi LiYanhong ShiMargarita GutovaKaren Aboody, Behnam BadieStephen J. FormanMichael E. Barish & Christine E. Brown. (2020) Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Science Translational Medicine 12:533.
Crossref
Prativa Sahoo, Xin Yang, Daniel Abler, Davide Maestrini, Vikram Adhikarla, David Frankhouser, Heyrim Cho, Vanessa Machuca, Dongrui Wang, Michael Barish, Margarita Gutova, Sergio Branciamore, Christine E. Brown & Russell C. Rockne. (2020) Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. Journal of The Royal Society Interface 17:162, pages 20190734.
Crossref
Nasheed M. Hossain & Michael I. Nishimura. (2020) Late Events After CD-19 CAR-T Treatment. Biology of Blood and Marrow Transplantation 26:1, pages e1-e2.
Crossref
Jacob S. Appelbaum, Navin Pinto & Rimas J. Orentas. 2020. Chimeric Antigen Receptor T-Cell Therapies for Cancer. Chimeric Antigen Receptor T-Cell Therapies for Cancer 137 163 .
Katie L. Owen, Natasha K. Brockwell & Belinda S. Parker. 2020. Encyclopedia of Bone Biology. Encyclopedia of Bone Biology 421 437 .
Lawrence A. Stern, Vanessa D. Jonsson & Saul J. Priceman. 2020. Tumor Microenvironment. Tumor Microenvironment 297 326 .
Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini, Giovanni Martinelli & Ugo De Giorgi. (2019) CAR-T cell therapy: a potential new strategy against prostate cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Feifei Qi, Yanping Ding, Xin-an Lu, Yuqin Song & Jun Zhu. (2019) Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma. Molecular Therapy - Oncolytics 15, pages 60-68.
Crossref
Emiliano Roselli, Jeremy S. Frieling, Konrad Thorner, María C. Ramello, Conor C. Lynch & Daniel Abate-Daga. (2019) CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms. BioDrugs 33:6, pages 647-659.
Crossref
Dan Li, Xue Li, Wei-Lin Zhou, Yong Huang, Xiao Liang, Lin Jiang, Xiao Yang, Jie Sun, Zonghai Li, Wei-Dong Han & Wei Wang. (2019) Genetically engineered T cells for cancer immunotherapy. Signal Transduction and Targeted Therapy 4:1.
Crossref
Adeline N. Boettcher, Ahmed Usman, Alicia Morgans, David J. VanderWeele, Jeffrey Sosman & Jennifer D. Wu. (2019) Past, Current, and Future of Immunotherapies for Prostate Cancer. Frontiers in Oncology 9.
Crossref
Robbie G. Majzner & Crystal L. Mackall. (2019) Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine 25:9, pages 1341-1355.
Crossref
Zachary Walsh, Yinmeng Yang & M. Eric Kohler. (2019) Immunobiology of chimeric antigen receptor T cells and novel designs. Immunological Reviews 290:1, pages 100-113.
Crossref
Mohamad Hamieh, Anton Dobrin, Annalisa Cabriolu, Sjoukje J. C. van der Stegen, Theodoros Giavridis, Jorge Mansilla-Soto, Justin Eyquem, Zeguo Zhao, Benjamin M. Whitlock, Matthew M. Miele, Zhuoning Li, Kristen M. Cunanan, Morgan Huse, Ronald C. Hendrickson, Xiuyan Wang, Isabelle Rivière & Michel Sadelain. (2019) CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568:7750, pages 112-116.
Crossref
Yingjuan J. Lu, Haiyan Chu, Leroy W. Wheeler, Melissa Nelson, Elaine Westrick, James F. Matthaei, Ian I. Cardle, Adam Johnson, Joshua Gustafson, Nikki Parker, Marilynn Vetzel, Le-Cun Xu, Emilia Z. Wang, Michael C. Jensen, Patrick J. Klein, Philip S. Low & Christopher P. Leamon. (2019) Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. Frontiers in Oncology 9.
Crossref
Marina Martinez & Edmund Kyung Moon. (2019) CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Frontiers in Immunology 10.
Crossref
Tiffany Seto, Danny Sam & Minggui Pan. (2019) Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. Medical Sciences 7:2, pages 14.
Crossref
Fabio Cofano, Matteo Monticelli, Marco Ajello, Francesco Zenga, Nicola Marengo, Giuseppe Di Perna, Roberto Altieri, Paola Cassoni, Luca Bertero, Antonio Melcarne, Fulvio Tartara, Alessandro Ducati & Diego Garbossa. (2019) The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control 26:1, pages 107327481987054.
Crossref
John P. Murad, Anna K. Kozlowska, Hee Jun Lee, Maya Ramamurthy, Wen-Chung Chang, Paul Yazaki, David Colcher, John Shively, Mihaela Cristea, Stephen J. Forman & Saul J. Priceman. (2018) Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Frontiers in Immunology 9.
Crossref
Michael R. Weist, Renate Starr, Brenda Aguilar, Junie Chea, Joshua K. Miles, Erasmus Poku, Ethan Gerdts, Xin Yang, Saul J. Priceman, Stephen J. Forman, David Colcher, Christine E. Brown & John E. Shively. (2018) PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89 Zr-Oxine . Journal of Nuclear Medicine 59:10, pages 1531-1537.
Crossref
Alice Crane, Sudhir Isharwal & Hui Zhu. (2018) Current Therapeutic Strategies in Clinical Urology. Molecular Pharmaceutics 15:8, pages 3010-3019.
Crossref
Sander Frank, Peter Nelson & Valeri Vasioukhin. (2018) Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. F1000Research 7, pages 1173.
Crossref
Morgan Pantuck, Nicolaos Palaskas & Alexandra Drakaki. (2018) Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success. Cancer Treatment and Research Communications 17, pages 1-7.
Crossref
Morgan Pantuck, Nicolaos Palaskas & Alexandra Drakaki. (2018) Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art. Cancer Treatment and Research Communications 17, pages 8-12.
Crossref